^
Association details:
| Biomarker: | CXCL8 elevation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 2000: Systemic and tumor associated IL-8 correlates with resistance to PD-L1 blockade
Published date:
05/15/2020
Excerpt:
High levels of IL-8 in plasma, PBMCs and tumors, were associated with decreased efficacy in mUC and mRCC patients treated with atezolizumab, even in tumors that were classically CD8+ T cell inflamed.
DOI:
10.1158/1538-7445.AM2020-2000
